New research shows that commonly prescribed cholesterol-lowering drugs known as statins can directly alter a protein in muscle cells and trigger a continuous flow of calcium. The finding, obtained using advanced imaging techniques, links the drugs’ interaction with a muscle protein to an abnormal opening of a channel that normally regulates calcium movement, a process now implicated in the muscle pain, weakness and rare severe damage reported by some patients.
The imaging allowed scientists to observe the drug interacting at the cellular level and to trace the downstream effect: when the channel is forced open, calcium floods the muscle cell and is not properly contained. Sustained calcium leakage disrupts normal cellular function and can damage muscle tissue, providing a mechanistic explanation for symptoms long associated with statin therapy.
Statins are widely used to reduce the risk of heart attacks and strokes, and muscle complaints have been a persistent clinical issue. By identifying a concrete molecular mechanism, the study clarifies why those adverse effects may arise in a subset of users. The discovery also offers a defined biological process for researchers and drug developers to investigate when seeking ways to limit muscle-related side effects while preserving the cardiovascular benefits of the medications.
Translating this insight into clinical practice will require additional work to determine which patients are most susceptible and how the interaction varies among different statins or dosing regimens. The molecular picture revealed by the study provides a foundation for such follow-up research and for efforts to design therapies or screening approaches that reduce the risk of muscle injury without compromising the drugs’ protective effects against cardiovascular disease.
